CMO Levi Garraway (Genentech)
Focusing on the bright side, FDA OKs Roche's Actemra for rare lung disease despite PhIII flop
Actemra’s failure to hit the primary endpoint in a Phase III study didn’t stop the FDA from granting Roche priority review. And it’s certainly not …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
